For Healthcare Professionals

A Study to Investigate LYL845 in Adults With Solid Tumors


About the study

This is an open-label, multi-center, dose-escalation study with expansion cohorts, designed to evaluate the safety and anti-tumor activity of LYL845, an epigenetically reprogrammed tumor infiltrating lymphocyte (TIL) therapy, in participants with relapsed or refractory (R/R) metastatic or locally advanced melanoma, non-small cell lung cancer (NSCLC), and colorectal cancer (CRC).

Who can take part

You may be eligible to participate in the study if you meet the following criteria:


Inclusion Criteria:

  1. Age ≥ 18 years up to ≤ 75 years at the time of informed consent
  2. Confirmed diagnosis of melanoma, non-small cell lung cancer (NSCLC), or colorectal cancer (CRC) that is metastatic or locally advanced or unresectable and is relapsed and/or refractory (R/R) after standard therapy for each tumor histology
  3. Participants must have received prior systemic treatment for their metastatic disease or locally advanced disease based on tumor type as follows:
  4. Melanoma: participants with disease progression following an immune checkpoint inhibitor (CPI) and if BRAF-mutated, BRAF/MEK inhibition
  5. NSCLC: participants with disease progression following at least 1 approved systemic therapy, including an immune CPI-containing regimen for appropriate patients or an approved targeted therapy for known molecular abnormalities if applicable to their disease
  6. CRC: participants with disease progression following at least 1 line of therapy, including a fluoropyrimidine with oxaliplatin or irinotecan. Microsatellite instability (MSI) high/mismatch repair deficient (dMMR) CRC participants must have disease progression following systemic therapy with immune CPIs.
  7. Measurable disease including at least 1 lesion that is safely resectable AND a target lesion to measure response and an additional lesion for biopsy
  8. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  9. Adequate organ and marrow function
  10. Women of childbearing potential must have a negative pregnancy test at screening
  11. All participants must agree to practice highly effective methods of contraception


Exclusion Criteria:

  1. Prior treatment with adoptive cellular therapy
  2. Prior solid organ transplantation
  3. Central nervous system (CNS) involvement of disease that is extensive, symptomatic or untreated, or patients with leptomeningeal disease
  4. Uncontrolled or symptomatic pleural effusion or ascites
  5. Untreated or active systemic infection
  6. Active autoimmune disease requiring treatment or primary immunodeficiency syndrome
  7. Systemic corticosteroids at a dose of >10 mg of prednisone or equivalent per day
  8. Other primary malignancy within 3 years prior to enrollment
  9. Impaired cardiac function or clinically significant cardiovascular disease
  10. Required chronic anticoagulation, such as warfarin, low molecular weight heparin, or Factor Xa inhibitors
  11. Pregnant or nursing (lactating) women
pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply

Contact the study center to learn if this study is a good match for you.
Phone iconCall 888-707-7917Email iconEmail Study Center

Study’s details


Melanoma,Non-small Cell Lung Cancer,Colorectal Cancer

Age (in years)

18 - 75


Phase 1

Participants needed


Est. Completion Date

Sep 30, 2027

Treatment type



Lyell Immunopharma, Inc. identifier


Study number


Understanding Clinical Trials

Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?


Sign up to save your favorites, 
receive newsletters, resources, and alerts 
about clinical trials related to your conditions of interest.